Clinical Trials Logo

Multiple Indications Cancer clinical trials

View clinical trials related to Multiple Indications Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT03161613 Withdrawn - Clinical trials for Multiple Indications Cancer

Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

Start date: July 17, 2017
Phase:
Study type: Observational

This is a post-marketing study of patients who started nivolumab as first- or second-line therapy for metastatic melanoma or as second-line therapy for metastatic squamous non-small cell lung cancer (SqNSCLC) , metastatic non-SqNSCLC, metastatic renal cell carcimona (RCC), or recurrent or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN), or third-line therapy for classical Hodgkin lymphoma (cHL) in Mexico.

NCT ID: NCT02297139 Completed - Clinical trials for Multiple Indications Cancer

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Start date: July 31, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.